No Data
Exelixis Analyst Ratings
Exelixis Gains After Win in Patent Fight With MSN Over Cabometyx
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
Exelixis Shares Resume Trade Following Circuit Breaker Halt
Jasper Gains 11% on Data for Briquilimab in Urticaria
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.